Raras
Buscar doenças, sintomas, genes...
Ataxia espinocerebelar tipo 17
ORPHA:98759CID-10 · G11.8CID-11 · 8A03.16OMIM 164700DOENÇA RARA

É uma variação rara da ataxia cerebelar autossômica dominante tipo I (ADCA tipo I), uma doença neurológica hereditária dominante. Ela se manifesta com um quadro clínico variável que pode incluir demência, problemas psiquiátricos, sintomas parecidos com os do Parkinson, distonia (movimentos musculares involuntários e repetitivos), coreia (movimentos incontroláveis e bruscos), espasticidade (rigidez muscular) e epilepsia.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma variação rara da ataxia cerebelar autossômica dominante tipo I (ADCA tipo I), uma doença neurológica hereditária dominante. Ela se manifesta com um quadro clínico variável que pode incluir demência, problemas psiquiátricos, sintomas parecidos com os do Parkinson, distonia (movimentos musculares involuntários e repetitivos), coreia (movimentos incontroláveis e bruscos), espasticidade (rigidez muscular) e epilepsia.

Pesquisas ativas
1 ensaio
2 total registrados no ClinicalTrials.gov
Publicações científicas
97 artigos
Último publicado: 2026 Mar 17

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
100
pacientes catalogados
Início
All ages
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G11.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
19 sintomas
💪
Músculos
3 sintomas
🫘
Rins
1 sintomas
👁️
Olhos
1 sintomas
🫃
Digestivo
1 sintomas

+ 21 sintomas em outras categorias

Características mais comuns

90%prev.
Ataxia
Muito frequente (99-80%)
90%prev.
Distúrbio da marcha
Muito frequente (99-80%)
55%prev.
Distonia
Frequente (79-30%)
55%prev.
Atrofia/hipoplasia cerebral generalizada
Frequente (79-30%)
55%prev.
Cãibra do escrivão
Frequente (79-30%)
55%prev.
Atrofia/Degeneração afetando o tronco cerebral
Frequente (79-30%)
46sintomas
Muito frequente (2)
Frequente (17)
Sem dados (27)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 46 características clínicas mais associadas, ordenadas por frequência.

Ataxia
Muito frequente (99-80%)90%
Distúrbio da marchaGait disturbance
Muito frequente (99-80%)90%
DistoniaDystonia
Frequente (79-30%)55%
Atrofia/hipoplasia cerebral generalizadaGeneralized cerebral atrophy/hypoplasia
Frequente (79-30%)55%
Cãibra do escrivãoWriter's cramp
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico97PubMed
Últimos 10 anos40publicações
Pico20166 papers
Linha do tempo
2026Hoje · 2026🧪 2010Primeiro ensaio clínico📈 2016Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

TBPTATA-box-binding proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:2194289, PubMed:2363050, PubMed:2374612, PubMed:27193682, PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2,

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 17

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA17 is an autosomal dominant cerebellar ataxia (ADCA) characterized by widespread cerebral and cerebellar atrophy, dementia and extrapyramidal signs. The molecular defect in SCA17 is the expansion of a CAG repeat in the coding region of TBP. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
52.5 TPM
Linfócitos
28.7 TPM
Fallopian Tube
26.9 TPM
Útero
24.9 TPM
Ovário
24.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia type 17late-onset Parkinson disease
HGNC:11588UniProt:P20226

Variantes genéticas (ClinVar)

90 variantes patogênicas registradas no ClinVar.

🧬 TBP: GRCh38/hg38 6q25.2-27(chr6:153483970-170605209)x3 ()
🧬 TBP: GRCh38/hg38 6q27(chr6:167201522-170610382)x1 ()
🧬 TBP: GRCh38/hg38 6q24.2-27(chr6:144488859-170610382)x3 ()
🧬 TBP: NM_003194.5(TBP):c.586-13C>G ()
🧬 TBP: NM_003194.5(TBP):c.498-9C>G ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 11 variantes classificadas pelo ClinVar.

4
3
4
Patogênica (36.4%)
VUS (27.3%)
Benigna (36.4%)
VARIANTES MAIS SIGNIFICATIVAS
LOC108663996: NM_003194.5(TBP):c.215_216insGCAACAACAACAGCAGCAGCAGCAGCAGCAGCAGCAGCA (p.Gln95_Al... [Pathogenic]
LOC108663996: NM_003194.5(TBP):c.225GCA[25] (p.Gln95_Ala96insGlnGlnGlnGlnGlnGln) [Pathogenic]
LOC108663996: NM_003194.5(TBP):c.221_222insGC (p.Gln75fs) [Conflicting classifications of pathogenicity]
LOC108663996: NG_008165.1:g.12526CAR[46_?] [Pathogenic; risk factor]
LOC108663996: NM_003194.5(TBP):c.216_217insT (p.Gln73fs) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 21
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Ataxia espinocerebelar tipo 17

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

2 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
41 papers (10 anos)
#1

Childhood-Onset Huntington's Disease-Like Presentation of SCA17 with Intermediate Repeats, A Case Report.

Cerebellum (London, England)2026 Mar 17

Objectives: In Spinocerebellar Ataxia type 17 (SCA17), penetrance is determined by repeat number of the CAG/CAA trinucleotide in the TATA-binding protein (TBP) gene. The intermediate range (41–48) exhibits only partial penetrance but may manifest a Huntington’s disease-like (HDL-4) syndrome with onset at age 50–60 years. We report a unique case of HDL-4 with childhood onset despite intermediate range repeats. Methods: This patient was evaluated at the University of Minnesota Movement Disorders Clinic. Standard Protocol Approvals, Registrations, and Patient Consents: Informed consent to disclose was obtained from the legal guardian of the subject of this report. Results: A 14-year-old male of Chinese descent presented with generalized dystonic and choreoathetoid movements since age 11 alongside motor delays, epilepsy, and speech, balance, and coordination dysfunction since infancy. Family history was limited given his adoptive status. Subsequent workup confirmed SCA17 with repeat numbers of 43 and 37 in the intermediate range. Discussion: This is the first case of intermediate range SCA17 of childhood-onset, emphasizing the evolving classification of intermediate vs. full penetrance while suggesting that the TBP repeat length may not be the sole determinant of disease onset and severity. It also highlights the importance of repeat expansion panels when investigating complex movement disorders.

#2

Isolated Generalized Chorea in a Patient with Small-Expanded Allele Spinocerebellar Ataxia 17.

Cerebellum (London, England)2025 Jun 06

Spinocerebellar ataxia type 17 (SCA17) is an autosomal dominant disease caused by a polyglutamine-encoding CAG/CAA repeat expansion within the TATA box-binding protein (TBP) gene. It is characterized by a markedly heterogeneous phenomenology and complex genotype-phenotype relationships. We describe the clinical, neuropsychological, and neuroimaging findings of a 73-year-old patient who presented a 10-year history of generalized hyperkinetic movements and depressive symptoms. The patient's family history was unremarkable. Neurological examination revealed choreic movements affecting the upper and lower limbs, the face and the trunk with no additional neurological signs. Blood sample analysis, brain imaging, and neuropsychological evaluation revealed normal results. Genetic analysis identified, in the TBP gene, the 41-CAG pathological allele with reduced penetrance. The present case report provides further insight into the small-expanded allele SCA17-associated phenotype, supporting the recently updated genotype-phenotype assessment for SCA17.

#3

TBP Repeat Expansion Analysis in Patients Carrying Heterozygous STUB1 Variants.

Movement disorders : official journal of the Movement Disorder Society2025 May

The cooccurrence of intermediate (40-49 CAG/CAA) TBP repeat expansions with STUB1 variants questions the pathogenicity of monoallelic STUB1 variants in cerebellar ataxia. The objective of this study was to describe the phenotypic spectrum of heterozygous STUB1 variants with or without intermediate TBP repeat expansions. We determined the presence of TBP repeat expansions and STUB1 variants in six families with cerebellar ataxia. Cooccurrence of both genotypes in one family resulted in cerebellar ataxia, involving cognitive and extrapyramidal complications. Variable degrees of cerebellar ataxia and cognitive impairment were found in four families carrying a heterozygous STUB1 variant and normal TBP alleles. Finally, we report one patient with a mild late-onset cerebellar ataxia carrying an intermediate expanded TBP allele without the presence of a STUB1 variant. Heterozygous STUB1 variants are associated with a milder phenotype and reduced penetrance compared with the cosegregation with intermediate TBP alleles, which causes a fully penetrant complicated form of cerebellar ataxia. © 2025 International Parkinson and Movement Disorder Society.

#4

Molecular Mechanisms of Spinocerebellar Ataxia Type 17.

Molecular neurobiology2025 May

Spinocerebellar ataxia type 17 (SCA17) is a hereditary neurodegenerative disorder characterized by progressive motor and cognitive decline, leading to severe disability and death. SCA17 is caused by a CAG repeat expansion mutation in the TBP gene, resulting in the production of an abnormally long polyglutamine tract, which classifies it as a polyglutamine disorder. At present, there is no effective treatment for SCA17, and existing therapies provide only symptomatic relief. While the exact pathogenic mechanisms of SCA17 remain unclear, the TBP mutation affects a well-characterized transcription factor, making it an ideal model for studying polyglutamine-related neurodegeneration. Here, we review the clinical features of SCA17 and explore proposed mechanisms of its pathogenesis.

#5

The New Face of Dynamic Mutation-The CAA [CAG]n CAA CAG Motif as a Mutable Unit in the TBP Gene Causative for Spino-Cerebellar Ataxia Type 17.

International journal of molecular sciences2024 Jul 26

Since 1991, several genetic disorders caused by unstable trinucleotide repeats (TNRs) have been identified, collectively referred to as triplet repeat diseases (TREDs). They share a common mutation mechanism: the expansion of repeats (dynamic mutations) due to the propensity of repeated sequences to form unusual DNA structures during replication. TREDs are characterized as neurodegenerative diseases or complex syndromes with significant neurological components. Spinocerebellar ataxia type 17 (SCA17) falls into the former category and is caused by the expansion of mixed CAA/CAG repeats in the TBP gene. To date, a five-unit organization of this region [(CAG)3 (CAA)3] [(CAG)n] [CAA CAG CAA] [(CAG)n] [CAA CAG], with expansion in the second [(CAG)n] unit being the most common, has been proposed. In this study, we propose an alternative organization scheme for the repeats. A search of the PubMed database was conducted to identify articles reporting both the number and composition of GAC/CAA repeats in TBP alleles. Nineteen reports were selected. The sequences of all identified CAG/CAA repeats in the TBP locus, including 67 cases (probands and b relatives), were analyzed in terms of their repetition structure and stability in inheritance, if possible. Based on the analysis of three units [(CAG)3 (CAA)2] [CAA (CAG)n CAA CAG] [CAA (CAG)n CAA CAG], the organization of repeats is proposed. Detailed analysis of the CAG/CAA repeat structure, not just the number of repeats, in TBP-expanded alleles should be performed, as it may have a prognostic value in the prediction of stability/instability during transmission and the possible anticipation of the disease.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC51 artigos no totalmostrando 40

2026

Childhood-Onset Huntington's Disease-Like Presentation of SCA17 with Intermediate Repeats, A Case Report.

Cerebellum (London, England)
2025

Isolated Generalized Chorea in a Patient with Small-Expanded Allele Spinocerebellar Ataxia 17.

Cerebellum (London, England)
2025

TBP Repeat Expansion Analysis in Patients Carrying Heterozygous STUB1 Variants.

Movement disorders : official journal of the Movement Disorder Society
2025

Molecular Mechanisms of Spinocerebellar Ataxia Type 17.

Molecular neurobiology
2024

The New Face of Dynamic Mutation-The CAA [CAG]n CAA CAG Motif as a Mutable Unit in the TBP Gene Causative for Spino-Cerebellar Ataxia Type 17.

International journal of molecular sciences
2024

Antisaccades in Spinocerebellar Ataxia Type 17 With Middle Cerebellar Peduncle Hyperintensities Without Hot-Cross-Bun Sign.

Journal of clinical neurology (Seoul, Korea)
2024

Dilemma in differentiation of spinocerebellar ataxia type 17 from Huntington's disease: comorbidity or independent disease?

The International journal of neuroscience
2023

Phenotypic defects from the expression of wild-type and pathogenic TATA-binding proteins in new Drosophila models of Spinocerebellar Ataxia Type 17.

G3 (Bethesda, Md.)
2023

Spinocerebellar Ataxia type 17 presenting with progressive myoclonic epilepsy.

eNeurologicalSci
2022

Spinocerebellar ataxia type 17-digenic TBP/STUB1 disease: neuropathologic features of an autopsied patient.

Acta neuropathologica communications
2023

Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.

Movement disorders : official journal of the Movement Disorder Society
2022

Mutation analysis of the TATA box-binding protein (TBP) gene in Russian patients with spinocerebellar ataxia and Huntington disease-like phenotype.

Clinical neurology and neurosurgery
2022

Calpains as novel players in the molecular pathogenesis of spinocerebellar ataxia type 17.

Cellular and molecular life sciences : CMLS
2023

Ocular Motor Findings Aid in Differentiation of Spinocerebellar Ataxia Type 17 from Huntington's Disease.

Cerebellum (London, England)
2022

Digenic inheritance of STUB1 variants and TBP polyglutamine expansions explains the incomplete penetrance of SCA17 and SCA48.

Genetics in medicine : official journal of the American College of Medical Genetics
2022

Small-Expanded Allele Spinocerebellar Ataxia Type 17 Leading to Broad Movement Disorder Phenotype in a Brazilian Patient.

Cerebellum (London, England)
2022

Very late-onset sporadic spinocerebellar ataxia type 17.

Acta neurologica Belgica
2020

ERK activation precedes Purkinje cell loss in mice with Spinocerebellar ataxia type 17.

Neuroscience letters
2020

New Synthetic 3-Benzoyl-5-Hydroxy-2H-Chromen-2-One (LM-031) Inhibits Polyglutamine Aggregation and Promotes Neurite Outgrowth through Enhancement of CREB, NRF2, and Reduction of AMPKα in SCA17 Cell Models.

Oxidative medicine and cellular longevity
2019

Molecular Mechanisms and Therapeutics for SCA17.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2019

Spinocerebellar ataxia 48 presenting with ataxia associated with cognitive, psychiatric, and extrapyramidal features: A report of two Italian families.

Parkinsonism &amp; related disorders
2019

Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models.

Aging
2019

Occurrence of Stridor During Sleep in a Patient With Spinocerebellar Ataxia Type 17.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2019

The Expanding Clinical Universe of Polyglutamine Disease.

The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
2018

Complexity of the Genetics and Clinical Presentation of Spinocerebellar Ataxia 17.

Frontiers in cellular neuroscience
2018

The indole compound NC009-1 inhibits aggregation and promotes neurite outgrowth through enhancement of HSPB1 in SCA17 cells and ameliorates the behavioral deficits in SCA17 mice.

Neurotoxicology
2018

Spinocerebellar Ataxia Type 17 (SCA17).

Advances in experimental medicine and biology
2018

Home-cage anxiety levels in a transgenic rat model for Spinocerebellar ataxia type 17 measured by an approach-avoidance task: The light spot test.

Journal of neuroscience methods
2017

Anxiety and risk assessment-related traits in a rat model of Spinocerebellar ataxia type 17.

Behavioural brain research
2017

Genetically modified rodent models of SCA17.

Journal of neuroscience research
2017

Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat.

Journal of psychopharmacology (Oxford, England)
2016

Trinucleotide repeat expansion of TATA-binding protein gene associated with Parkinson's disease: A Thai multicenter study.

Parkinsonism &amp; related disorders
2016

Targeting the prodromal stage of spinocerebellar ataxia type 17 mice: G-CSF in the prevention of motor deficits via upregulating chaperone and autophagy levels.

Brain research
2016

Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17.

Drug design, development and therapy
2016

Huntington's Disease, Huntington's Disease Look-Alikes‎, and Benign Hereditary Chorea: What's New?

Movement disorders clinical practice
2016

Automated quantitative analysis to assess motor function in different rat models of impaired coordination and ataxia.

Journal of neuroscience methods
2016

A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.

Parkinsonism &amp; related disorders
2015

The potential of lactulose and melibiose, two novel trehalase-indigestible and autophagy-inducing disaccharides, for polyQ-mediated neurodegenerative disease treatment.

Neurotoxicology
2015

Trehalose attenuates the gait ataxia and gliosis of spinocerebellar ataxia type 17 mice.

Neurochemical research
2015

Excessive brain iron accumulation in spinocerebellar ataxia type 17.

Neurology
Ver todos os 51 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Ataxia espinocerebelar tipo 17.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Ataxia espinocerebelar tipo 17

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Childhood-Onset Huntington's Disease-Like Presentation of SCA17 with Intermediate Repeats, A Case Report.
    Cerebellum (London, England)· 2026· PMID 41843312mais citado
  2. Isolated Generalized Chorea in a Patient with Small-Expanded Allele Spinocerebellar Ataxia 17.
    Cerebellum (London, England)· 2025· PMID 40478462mais citado
  3. TBP Repeat Expansion Analysis in Patients Carrying Heterozygous STUB1 Variants.
    Movement disorders : official journal of the Movement Disorder Society· 2025· PMID 39950762mais citado
  4. Molecular Mechanisms of Spinocerebellar Ataxia Type 17.
    Molecular neurobiology· 2025· PMID 39614971mais citado
  5. The New Face of Dynamic Mutation-The CAA [CAG]n CAA CAG Motif as a Mutable Unit in the TBP Gene Causative for Spino-Cerebellar Ataxia Type 17.
    International journal of molecular sciences· 2024· PMID 39125760mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98759(Orphanet)
  2. OMIM OMIM:164700(OMIM)
  3. MONDO:0011781(MONDO)
  4. GARD:10469(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q21097864(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Ataxia espinocerebelar tipo 17
Compêndio · Raras BR

Ataxia espinocerebelar tipo 17

ORPHA:98759 · MONDO:0011781
Prevalência
<1 / 1 000 000
Casos
100 casos conhecidos
Herança
Autosomal dominant
CID-10
G11.8 · Outras ataxias hereditárias
CID-11
Ensaios
1 ativos
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1846707
Repurposing
1 candidato
taltirelinthyrotropin releasing hormone receptor agonist
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades